Management of Impaired Fasting Glucose
Patients with impaired fasting glucose (IFG, defined as fasting glucose 100-125 mg/dL or 5.6-6.9 mmol/L) should be immediately referred to an intensive lifestyle modification program targeting 7% body weight loss and at least 150 minutes per week of moderate-intensity physical activity, with metformin therapy considered for those with BMI >35 kg/m², age <60 years, or women with prior gestational diabetes. 1
Diagnostic Criteria and Target Levels
IFG is defined as fasting glucose levels between 100-125 mg/dL (5.6-6.9 mmol/L) 2. This represents an intermediate stage before type 2 diabetes develops. The target for management is to prevent progression to diabetes, not to achieve a specific fasting glucose number in the IFG range itself.
Important caveat: There are two competing diagnostic thresholds for IFG:
- WHO criteria: ≥6.1 mmol/L (110 mg/dL)
- ADA criteria: ≥5.6 mmol/L (100 mg/dL)
Evidence suggests the lower ADA threshold (5.6 mmol/L) may be more appropriate for high-risk populations, as using the 6.1 mmol/L cutoff would miss over 25% of individuals with dysglycemia 3.
Primary Management Strategy: Intensive Lifestyle Modification
The cornerstone of IFG management is intensive lifestyle intervention, which has demonstrated:
- 58% reduction in diabetes onset at 3 years
- 43% sustained reduction at 20 years (Da Qing study)
- 34% sustained reduction at 10 years (Diabetes Prevention Program) 1
Specific Lifestyle Targets:
- Weight loss: 7% of body weight
- Physical activity: Minimum 150 minutes per week of moderate-intensity exercise (e.g., brisk walking)
- Follow-up counseling: Essential for success 1
These lifestyle interventions are more effective than pharmacotherapy and are cost-effective 1, 4. Lifestyle modification also improves lipid profiles and promotes weight loss beyond glycemic control 4.
Pharmacologic Therapy: Metformin
Metformin should be considered for diabetes prevention in specific high-risk subgroups 1:
Indications for Metformin:
- BMI >35 kg/m²
- Age <60 years
- Women with prior gestational diabetes
While metformin delays or prevents diabetes onset, it is less effective than lifestyle changes 2. The cost-effectiveness of metformin in IFG management remains uncertain 2, though the guideline recommends third-party payer coverage for prevention programs 1.
Alternative: Acarbose
Acarbose has also shown efficacy in delaying diabetes onset, though it is not as commonly recommended as metformin 2.
Monitoring and Additional Management
- Annual monitoring for progression to diabetes is recommended 1
- Screen and treat cardiovascular risk factors (hypertension, dyslipidemia) as IFG increases cardiovascular disease risk 1, 5
- Diabetes self-management education programs are appropriate venues for IFG patients to receive ongoing support 1
Common Pitfalls to Avoid
Do not use insulin for IFG management - The research on insulin glargine in IFG populations 6 is preliminary and not guideline-recommended. Insulin is reserved for established diabetes, not prediabetes.
Do not focus on achieving specific fasting glucose targets within the IFG range - The goal is diabetes prevention through lifestyle modification, not titrating to a particular fasting glucose number.
Do not overlook the 10-15% prevalence of IFG in U.S. adults 2 - Systematic screening of high-risk populations is essential.
Recognize ethnic differences - Asian populations show higher rates of isolated IGT compared to Caucasians, who have higher rates of isolated IFG 7. This may affect screening strategies but not management approach.
Risk Factors Warranting Screening
Screen patients with fasting plasma glucose if they have:
- Family history of diabetes
- BMI ≥25 kg/m²
- Sedentary lifestyle
- Hypertension or dyslipidemia
- History of gestational diabetes or large-for-gestational-age infant
- Polycystic ovary syndrome
- High-risk ethnicity (Black, Latin American, Native American, Asian-Pacific Islander) 2
The evidence strongly supports that intensive lifestyle modification is the first-line, most effective intervention for IFG, with metformin reserved for specific high-risk subgroups who meet the criteria outlined above.